Drug intelligence / Profile preview

budesonide + salmeterol + azithromycin

Development stage: Preclinical
Lead developer: AstraZeneca
Modality: Small Molecules
Administration: Inhalation, Oral, Intravenous

Overview

This is a combination therapy consisting of budesonide (a corticosteroid), salmeterol (a long-acting beta-2 agonist), and azithromycin (a macrolide antibiotic). While not available as a single commercial product, similar combinations have been studied for respiratory conditions. Budesonide works by reducing inflammation in the airways, salmeterol acts as a bronchodilator by relaxing airway muscles, and azithromycin provides both antimicrobial and anti-inflammatory effects.

Targets

GR (Glucocorticoid receptor)Bacterial 50S ribosomal subunitADRB2 (β2)

Beyond the preview

Go deeper on budesonide + salmeterol + azithromycin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on budesonide + salmeterol + azithromycin.

Explore the full profile